Cassava Sciences Inc. (SAVA) stock surged 8.5% in the pre-market trading session on Tuesday, rebounding from a massive 84% plunge on Friday. The biotech firm's shares had plummeted after disappointing results from a late-stage trial of its experimental Alzheimer's disease drug Simufilam.
The Phase 3 trial failed to meet its co-primary endpoints of cognitive and functional improvement in patients with mild-to-moderate Alzheimer's disease. Simufilam did not show a significant reduction in cognitive or functional decline compared to a placebo during the 52-week study.
Despite the rebound, Cassava Sciences' stock remains well below its pre-trial levels as investors digest the implications of the failed drug trial. The company's future prospects now hinge on its ability to develop alternative treatments or pivot its research focus.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。